AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-100 | >>
Results: 1-25/101
A PHASE-II TRIAL OF OUTPATIENT SUBCUTANEOUS GM-CSF, INTERLEUKIN-2, AND INTERFERON-ALPHA PLUS ORAL CIS-RETINOIC ACID IN PATIENTS WITH METASTATIC RENAL-CELL CANCER
Authors: RYAN CW VOGELZANG NJ DUMAS MC STADLER WM
Citation: Cw. Ryan et al., A PHASE-II TRIAL OF OUTPATIENT SUBCUTANEOUS GM-CSF, INTERLEUKIN-2, AND INTERFERON-ALPHA PLUS ORAL CIS-RETINOIC ACID IN PATIENTS WITH METASTATIC RENAL-CELL CANCER, Journal of investigative medicine, 46(7), 1998, pp. 274-274
PHASE-II AND PHARMACODYNAMIC STUDIES OF PYRAZINE DIAZOHYDROXIDE (NSC-361456) IN PATIENTS WITH ADVANCED RENAL AND COLORECTAL-CANCER
Authors: VOGELZANG NJ MANI S SCHILSKY RL ANSARI RH TABER D RHINEHART SN GARCIA JC MEYER SC MICK R BROCKSTEIN BE STADLER WM RATAIN MJ VOKES EE
Citation: Nj. Vogelzang et al., PHASE-II AND PHARMACODYNAMIC STUDIES OF PYRAZINE DIAZOHYDROXIDE (NSC-361456) IN PATIENTS WITH ADVANCED RENAL AND COLORECTAL-CANCER, Clinical cancer research, 4(4), 1998, pp. 929-934
PHASE-II AND PHARMACODYNAMIC STUDIES OF PYRAZINE DIAZOHYDROXIDE (NSC-361456) IN PATIENTS WITH ADVANCED RENAL AND COLORECTAL-CANCER
Authors: VOGELZANG NJ MANI S SCHILSKY RL ANSARI RH TABER D RHINEHART SN GARCIA JC MEYER SC MICK R BROCKSTEIN BE STADLER WM RATAIN MJ VOKES EE
Citation: Nj. Vogelzang et al., PHASE-II AND PHARMACODYNAMIC STUDIES OF PYRAZINE DIAZOHYDROXIDE (NSC-361456) IN PATIENTS WITH ADVANCED RENAL AND COLORECTAL-CANCER, Clinical cancer research, 4(4), 1998, pp. 929-934
10.8 MG GOSERELIN EVERY 13 WEEKS FOR ADVANCED PROSTATE-CANCER
Authors: SAROSDY MF SCHELLHAMMER PF SOLOWAY MS VOGELZANG NJ CRAWFORD ED PRESTI J KELLEY P MITCHELL P PORTER L
Citation: Mf. Sarosdy et al., 10.8 MG GOSERELIN EVERY 13 WEEKS FOR ADVANCED PROSTATE-CANCER, Annals of oncology, 9, 1998, pp. 276-276
A PHASE-II STUDY OF 72 HOUR CONTINUOUS-INFUSION (CI) FLAVOPIRIDOL (FP) IN METASTATIC RENAL-CELL CARCINOMA (RCC)
Authors: STADLER WM LIEBOWITZ DN VOGELZANG NJ AMATO R SOSMAN J TABER D VOKES E
Citation: Wm. Stadler et al., A PHASE-II STUDY OF 72 HOUR CONTINUOUS-INFUSION (CI) FLAVOPIRIDOL (FP) IN METASTATIC RENAL-CELL CARCINOMA (RCC), Annals of oncology, 9, 1998, pp. 429-429
A PHASE-1 STUDY OF RALTITREXED (TOMUDEX(R)) AND PACLITAXEL
Authors: VOKES EE BERTUCCI D VOGELZANG NJ MANI S LOWERY C RATAIN MJ
Citation: Ee. Vokes et al., A PHASE-1 STUDY OF RALTITREXED (TOMUDEX(R)) AND PACLITAXEL, Annals of oncology, 9, 1998, pp. 462-462
SINGLE AND MULTIPLE-DOSE PHARMACOKINETICS OF SPI-77 (STEALTH(R) LIPOSOMAL CISPLATIN) GIVEN EVERY 3 WEEKS IN PATIENTS WITH ADVANCED CANCER
Authors: AMANTEA MA DEMARIO MD SCHWARTZ G VOGELZANG NJ TONDA M PENDYALA L RATAIN MJ
Citation: Ma. Amantea et al., SINGLE AND MULTIPLE-DOSE PHARMACOKINETICS OF SPI-77 (STEALTH(R) LIPOSOMAL CISPLATIN) GIVEN EVERY 3 WEEKS IN PATIENTS WITH ADVANCED CANCER, Annals of oncology, 9, 1998, pp. 465-465
A PHASE-I STUDY OF LIPOSOME-FORMULATED CISPLATIN (SPI-77(R)) GIVEN EVERY 3 WEEKS IN PATIENTS WITH ADVANCED CANCER
Authors: DEMARIO MD VOGELZANG NJ JANISCH L HUMPHRISS E MANI S TONDA M AMANTEA MA RATAIN MJ PENDYALA L
Citation: Md. Demario et al., A PHASE-I STUDY OF LIPOSOME-FORMULATED CISPLATIN (SPI-77(R)) GIVEN EVERY 3 WEEKS IN PATIENTS WITH ADVANCED CANCER, Annals of oncology, 9, 1998, pp. 466-466
PHASE-I STUDY OF CEP-2563 DIHYDROCHLORIDE (CEP-2563), A TYROSINE KINASE INHIBITOR, IN PATIENTS WITH SOLID TUMORS
Authors: MAUER AM VOGELZANG NJ JANISH L MANI S SAMARA E RATAIN MJ
Citation: Am. Mauer et al., PHASE-I STUDY OF CEP-2563 DIHYDROCHLORIDE (CEP-2563), A TYROSINE KINASE INHIBITOR, IN PATIENTS WITH SOLID TUMORS, Annals of oncology, 9, 1998, pp. 489-489
PHASE-I STUDY OF ZD9331 USING A 5-DAY SHORT INFUSION SCHEDULE
Authors: RATAIN MJ GOH BC SMITH R BERTUCCI D MANI S VOGELZANG NJ SCHILSKY RL HUTCHISON M DOUGLASS E
Citation: Mj. Ratain et al., PHASE-I STUDY OF ZD9331 USING A 5-DAY SHORT INFUSION SCHEDULE, Annals of oncology, 9, 1998, pp. 616-616
A PHASE-I TRIAL OF CONTINUOUS-INFUSION 5-FLUOROURACIL AND WEEKLY GEMCITABINE - UPDATED RESULTS OF AN ACTIVE COMBINATION FOR RENAL-CELL, HEPATOCELLULAR AND COLON-CARCINOMA
Authors: MANI S GORDON G VOGELZANG NJ BERTUCCI D SCHILSKY RL STADLER WM RATAIN MJ
Citation: S. Mani et al., A PHASE-I TRIAL OF CONTINUOUS-INFUSION 5-FLUOROURACIL AND WEEKLY GEMCITABINE - UPDATED RESULTS OF AN ACTIVE COMBINATION FOR RENAL-CELL, HEPATOCELLULAR AND COLON-CARCINOMA, Annals of oncology, 9, 1998, pp. 632-632
FATIGUE IN CANCER AND HIV AIDS - THE GROOPMAN ARTICLE REVIEWED/
Authors: VOGELZANG NJ
Citation: Nj. Vogelzang, FATIGUE IN CANCER AND HIV AIDS - THE GROOPMAN ARTICLE REVIEWED/, Oncology, 12(3), 1998, pp. 346
STUDY OF COHORT-SPECIFIC CONSENT AND PATIENT CONTROL IN PHASE-I CANCER TRIALS
Authors: DAUGHERTY CK RATAIN MJ MINAMI H BANIK DM VOGELZANG NJ STADER WM SIEGLER M
Citation: Ck. Daugherty et al., STUDY OF COHORT-SPECIFIC CONSENT AND PATIENT CONTROL IN PHASE-I CANCER TRIALS, Journal of clinical oncology, 16(7), 1998, pp. 2305-2312
MULTICENTER PHASE-II TRIAL OF INTERLEUKIN-2, INTERFERON-ALPHA, AND 13-CIS-RETINOIC ACID IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
Authors: STADLER WM KUZEL T DUMAS M VOGELZANG NJ
Citation: Wm. Stadler et al., MULTICENTER PHASE-II TRIAL OF INTERLEUKIN-2, INTERFERON-ALPHA, AND 13-CIS-RETINOIC ACID IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA, Journal of clinical oncology, 16(5), 1998, pp. 1820-1825
RANDOMIZED COMPARISON OF CISPLATIN AND ETOPOSIDE AND EITHER BLEOMYCINOR IFOSFAMIDE IN TREATMENT OF ADVANCED-DISSEMINATED GERM-CELL TUMORS - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP, SOUTHWEST-ONCOLOGY-GROUP, ANDCANCER AND LEUKEMIA GROUP-B STUDY
Authors: NICHOLS CR CATALANO PJ CRAWFORD ED VOGELZANG NJ EINHORN LH LOEHRER PJ
Citation: Cr. Nichols et al., RANDOMIZED COMPARISON OF CISPLATIN AND ETOPOSIDE AND EITHER BLEOMYCINOR IFOSFAMIDE IN TREATMENT OF ADVANCED-DISSEMINATED GERM-CELL TUMORS - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP, SOUTHWEST-ONCOLOGY-GROUP, ANDCANCER AND LEUKEMIA GROUP-B STUDY, Journal of clinical oncology, 16(4), 1998, pp. 1287-1293
KIDNEY CANCER
Authors: VOGELZANG NJ STADLER WM
Citation: Nj. Vogelzang et Wm. Stadler, KIDNEY CANCER, Lancet, 352(9141), 1998, pp. 1691-1696
COMPARISON OF GOSERELIN AND LEUPROLIDE IN COMBINED ANDROGEN BLOCKADE THERAPY
Authors: SAROSDY MF SCHELLHAMMER PF SHARIFI R BLOCK NL SOLOWAY MS VENNER PM PATTERSON AL VOGELZANG NJ CHODAK GW KLEIN EA SCHELLENGER JJ KOLVENBAG GJCM
Citation: Mf. Sarosdy et al., COMPARISON OF GOSERELIN AND LEUPROLIDE IN COMBINED ANDROGEN BLOCKADE THERAPY, Urology, 52(1), 1998, pp. 82-88
CYTOKINE THERAPY IN METASTATIC RENAL-CANCER
Authors: STADLER WM VOGELZANG NJ
Citation: Wm. Stadler et Nj. Vogelzang, CYTOKINE THERAPY IN METASTATIC RENAL-CANCER, The New England journal of medicine, 339(12), 1998, pp. 849-849
RADIATION-INDUCED RENAL-CELL CANCER - A REPORT OF 4 CASES AND REVIEW OF THE LITERATURE
Authors: VOGELZANG NJ YANG XM GOLDMAN S VIJAYAKUMAR S STEINBERG G
Citation: Nj. Vogelzang et al., RADIATION-INDUCED RENAL-CELL CANCER - A REPORT OF 4 CASES AND REVIEW OF THE LITERATURE, The Journal of urology, 160(6), 1998, pp. 1987-1990
COMPARISON OF GOSERELIN AND LEUPROLIDE IN COMBINED ANDROGEN BLOCKADE (CAB) FOR ADVANCED PROSTATE-CANCER
Authors: SAROSDY MF SCHELLHAMMER PF BLOCK NL SOLOWAY MS VENNER PM PATTERSON AL SHARIFI R VOGELZANG NJ CHODAK GW KLEIN EA SCHELLENGER JJ KOLVENBAG GJCM
Citation: Mf. Sarosdy et al., COMPARISON OF GOSERELIN AND LEUPROLIDE IN COMBINED ANDROGEN BLOCKADE (CAB) FOR ADVANCED PROSTATE-CANCER, The Journal of urology, 159(5), 1998, pp. 1300-1300
FACTORS PREDICTIVE OF SURVIVAL AMONG 337 PATIENTS WITH MESOTHELIOMA TREATED BETWEEN 1984 AND 1994 BY THE CANCER AND LEUKEMIA GROUP-B
Authors: HERNDON JE GREEN MR CHAHINIAN AP CORSON JM SUZUKI Y VOGELZANG NJ
Citation: Je. Herndon et al., FACTORS PREDICTIVE OF SURVIVAL AMONG 337 PATIENTS WITH MESOTHELIOMA TREATED BETWEEN 1984 AND 1994 BY THE CANCER AND LEUKEMIA GROUP-B, Chest, 113(3), 1998, pp. 723-731
A REVIEW OF CHEMOTHERAPY TRIALS FOR MALIGNANT MESOTHELIOMA
Authors: RYAN CW HERNDON J VOGELZANG NJ
Citation: Cw. Ryan et al., A REVIEW OF CHEMOTHERAPY TRIALS FOR MALIGNANT MESOTHELIOMA, Chest, 113(1), 1998, pp. 66-73
PHASE-I AND PHARMACOKINETIC STUDY OF IRINOTECAN (CPT-11) ADMINISTEREDWITH CYCLOSPORINE-A (CSA)
Authors: FAGBEMI S RATAIN MJ IYER L MANI S VOGELZANG NJ WANG X
Citation: S. Fagbemi et al., PHASE-I AND PHARMACOKINETIC STUDY OF IRINOTECAN (CPT-11) ADMINISTEREDWITH CYCLOSPORINE-A (CSA), Clinical pharmacology and therapeutics, 63(2), 1998, pp. 107-107
THE DYNAMICS OF PROSTATE-SPECIFIC ANTIGEN IN HORMONE-REFRACTORY PROSTATE CARCINOMA - AN ANALYSIS OF CANCER AND LEUKEMIA GROUP-B STUDY-9181 OF MEGESTROL-ACETATE
Authors: VOLLMER RT DAWSON NA VOGELZANG NJ
Citation: Rt. Vollmer et al., THE DYNAMICS OF PROSTATE-SPECIFIC ANTIGEN IN HORMONE-REFRACTORY PROSTATE CARCINOMA - AN ANALYSIS OF CANCER AND LEUKEMIA GROUP-B STUDY-9181 OF MEGESTROL-ACETATE, Cancer, 83(9), 1998, pp. 1989-1994
DIHYDRO-5-AZACYTIDINE AND CISPLATIN IN THE TREATMENT OF MALIGNANT MESOTHELIOMA - A PHASE-II STUDY BY THE CANCER AND LEUKEMIA GROUP-B
Authors: SAMUELS BL HERNDON JE HARMON DC CAREY R AISNER J CORSON JM SUZUKI Y GREEN MR VOGELZANG NJ
Citation: Bl. Samuels et al., DIHYDRO-5-AZACYTIDINE AND CISPLATIN IN THE TREATMENT OF MALIGNANT MESOTHELIOMA - A PHASE-II STUDY BY THE CANCER AND LEUKEMIA GROUP-B, Cancer, 82(8), 1998, pp. 1578-1584
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>